Immunex Corporation

Silverback Therapeutics, Inc.

Emergent Product Development Seattle,llc

Genentech, Inc.

Aptevo Research and Development LLC

Trubion Pharmaceuticals, Inc.

Araris Biotech Ag

Peter Robert Baum

William Christian Fanslow, Iii

M Patricia Beckmann

Stewart D Lyman

Sean Wesley Smith

Craig Alan Coburn

Joanne Louise Viney

Sabine Schadow Escobar

Peter Armstrong Thompson

Philip Tan

Valerie Odegard

Robert Dubose

Raymond G Goodwin

Brenda L Stevens

Richard B Gayle, Iii

Melissa K Carpenter

Erik Stephen Espling

William C Fanslow, Iii

John W Blankenship

Lynda Misher

Sateesh Kumar Natarajan

Alan Keith Lofquist

Adel Youakim

Timothy E Lofton

Brenda Stevens

Eric A Sorensen

Peter A Thompson

William Christian Iii Fanslow

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

Nectin-4 antibody conjugates and uses thereof

The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.

Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof

Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.

Benzazepine compounds, conjugates, and uses thereof

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

CD86 antagonist multi-target binding proteins

The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.

Methods of using BTL-II proteins

A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.

Antagonists of IL-6

Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.

Materials and methods for improved immunoglycoproteins

Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides.

C-type lectin polypeptide, polynucleotide and methods of making and use thereof

The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.

Antibodies that bind B7L-1

Growing community of inventors

Seattle, WA, United States of America

Peter Robert Baum